A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

A Phase Ia Single-center, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China

Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine.

This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an experimental recombinant staphylococcus aureus vaccine. The study will be carried out following a dose-escalation method from the low dosage to the high dosage, i.e. the higher dosage vaccine could only be administrated after the first seven-day safety of the lower dosage vaccine is confirmed after safety observation.

Study Overview

• Status: Completed
• Conditions: Staphylococcus Aureus Infection
• Intervention / Treatment: Biological: Placebo; Biological: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml); Biological: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml); Biological: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)

• Study Type: Interventional
• Enrollment (Actual): 144
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Taixing, Jiangsu, China, 210009
      • Xiaokui Hu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years).
• Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
• Able to understand the content of informed consent and willing to sign the informed consent.
• Able to complete the diary card independently.
• For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
• Axillary temperature ≤37.0°C.

Exclusion Criteria:

First Immunization exclusion standard:

• Prior receipt of Staphylococcus aureus vaccine
• Any confirmed Staphylococcus aureus infection disease in the past 12 month.
• History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
• Prior blood donation or Blood loss over 400ml in the last 3 months;
• Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
• History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain.
• Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease.
• Taking immunoglobulins and/or any blood products within the last 12 months.
• Asplenia, functional asplenia or asplenia caused by any situation or splenectomy.
• Any acute disease or acute attack of chronic disease in last 7 days.
• History of thyroidectomy or thyroid disease requiring treatment in the last 12 months.
• Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment)
• Participation in another research study involving receipt of an investigational product in the last 30 days.
• Woman who is breast-feeding.
• Prior administration of attenuated vaccine in last 28 days.
• Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
• Current anti-tuberculosis prophylaxis or therapy
• Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.

Following Immunization exclusion standard:

• Any grade 3 or more serious adverse reaction happen since the last vaccination.
• Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization.
• Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).
• According to the investigator, the participant should not continue participating in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Four doses of low dose vaccine; four doses of 15µg/0.6ml per dose	Biological: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
Experimental: Four doses of middle dose vaccine; four doses of 30µg/0.6ml per dose	Biological: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
Experimental: Four doses of high dose vaccine; four doses of 60µg/0.6ml per dose	Biological: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
Experimental: Three doses of low dose vaccine and one dose of placebo; three doses of 15µg/0.6ml per dose and one dose of placebo	Biological: Placebo; Biological: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
Experimental: Three doses of middle dose vaccine and one dose of placebo; three doses of 30µg/0.6ml per dose and one dose of placebo	Biological: Placebo; Biological: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
Experimental: Three doses of high dose vaccine and one dose of placebo; three doses of 60µg/0.6ml per dose and one dose of placebo	Biological: Placebo; Biological: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
Placebo Comparator: Four doses of placebo; four doses of placebo	Biological: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of injection site adverse reactions after vaccination	Occurrence of solicited injection site adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine	within 21 days after the vaccination
Occurrence of systematic adverse reactions after vaccination	Occurrence of solicited systematic adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine	within 21 days after the vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of serious adverse events after the vaccination.	Occurrence of serious adverse events within 6 months after the vaccination with the Recombinant Staphylococcus aureus vaccine	within 6 months after the vaccination
Occurrence of unsolicited adverse reactions after vaccination.	Occurrence of unsolicited adverse reactions within 42 days after vaccination with the Recombinant Staphylococcus aureus vaccine	within 42 days after the vaccination
Changes of the blood routine after vaccination.	Changes of the blood routine after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17.	day 0-17 after the vaccination
Changes of the blood biochemistry after vaccination.	Changes of the blood biochemistry after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17.	day 0-17 after the vaccination
Geometric mean titre against specific antigens	Geometric mean titre measured at day 0, 7, 14, 21, 42 and month 3, 6.	within 6 months after the vaccination
Geometric mean fold increase against specific antigens	Geometric mean fold increase measured at day 7, 14, 21, 42 and month 3, 6.	within 6 months after the vaccination
Positive conversion rate of serum against specific antigens	Positive conversion rate of serum measured at day 7, 14, 21, 42 and month 3, 6.	within 6 months after the vaccination

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination.	Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination with the Staphylococcus aureus vaccine at day at day 3, 7, 10, 14, 17, 21, 42 and month 3, 6.	within 6 months after the vaccination
Specific functional antibody responses to the Staphylococcus aureus vaccine	Specific functional antibody responses to the Staphylococcus aureus vaccine at day 7, 14, 21, 42 and month 3, 6.	within 6 months after the vaccination
Specific T cell immune responses to the Staphylococcus aureus vaccine.	Specific T cell immune responses to the Staphylococcus aureus vaccine at day at day7, 14, 21, 42 and month 3, 6 measured by ELISpot.	within 6 months after the vaccination

Collaborators and Investigators

• Sponsor: Jiangsu Province Centers for Disease Control and Prevention
• Collaborators: Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.

Publications and helpful links

General Publications

• Zhu FC, Zeng H, Li JX, Wang B, Meng FY, Yang F, Gu J, Liang HY, Hu YM, Liu P, Peng LS, Hu XK, Zhuang Y, Fan M, Li HB, Tan ZM, Luo P, Zhang P, Chu K, Zhang JY, Zeng M, Zou QM. Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials. Vaccine. 2022 May 20;40(23):3216-3227. doi: 10.1016/j.vaccine.2022.04.034. Epub 2022 Apr 23.

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2016
• Primary Completion (Actual): July 1, 2017
• Study Completion (Actual): September 1, 2017

Study Registration Dates

• First Submitted: June 11, 2016
• First Submitted That Met QC Criteria: June 16, 2016
• First Posted (Estimate): June 17, 2016

Study Record Updates

• Last Update Posted (Actual): October 17, 2017
• Last Update Submitted That Met QC Criteria: October 14, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Enterobacteriaceae Infections; Staphylococcal Infections; Escherichia coli Infections; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: JSVCT027

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO